AVNR’s AVP-825 meets primary endpoint in phase-3b migraine study: http://finance.yahoo.com/news/avanir-pharmaceuticals-announces-positive-outcome-080000787.html The PDUFA date for AVP-825 is 11/26/14. Seems like there's a lot of attention on migraine lately.